Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Fazel Shokri(Academic Center for Education, Culture and Research), Seyed Mohsen Razavi(Firoozgar General Hospital), Amir Hossein Daneshmanesh(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Lotta Hansson(Karolinska Institutet), Mahmood Jeddi‐Tehrani(Academic Center for Education, Culture and Research), Fariba Mozaffari(Karolinska University Hospital), Ramazan Ali Sharifian(University of Tehran), Ali Moshfegh(Karolinska University Hospital), Hodjattallah Rabbani(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital)
Cited by 15
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312